Metabolic syndrome is a common metabolic disorder associated with an increased incidence of obesity both in the world and in Croatia. The syndrome involves abdominal type of obesity, insulin resistance, hyperglycemia, dyslipidemia, hypertension, proinflammatory state, and prothrombotic state. The pathophysiology of the syndrome is based on insulin resistance and increased intake of fatty acids in the diet, resulting in the development of abdominal obesity. The syndrome is characterized by an increased risk of cardiovascular disease and type 2 diabetes. More recent findings also indicate the link between metabolic syndrome and the risk of developing type 1 diabetes mellitus (double diabetes). That is why regular follow ups, early recognition, and therapeutic interventions are needed at risk persons. The basic approach to this disorder is a change in life habits, weight loss, a balanced nutrition, and increased physical activity. If these measures do not achieve the target values of the individual components of the metabolic syndrome, drug therapy is started. The major groups of drugs used to treat metabolic syndrome are hypolipemics, antihypertensive agents, hypoglycemics, and medicines for the treatment of coagulation disorders. These medications, apart from affecting individual components of the metabolic syndrome with their basic mechanism of action, are beneficial to the body, reducing the inflammation and therefore the risk of complications.